MARKET INSIGHTS

Global nucleic acid solid phase synthesis carrier market was valued at USD 81.3 million in 2025 and is projected to reach USD 107 million by 2034, growing at a CAGR of 4.0% during the forecast period (2025–2034). These carriers serve as critical platforms for solid‑phase synthesis of nucleic acids, providing the necessary chemical framework for controlled synthesis of DNA and RNA strands.

These specialized carriers feature reactive chemical groups that bind to specific sites on nucleic acid chains, enabling sequential addition of nucleotides in solid‑phase synthesis.

Market growth is driven by increasing demand for synthetic nucleic acids in therapeutic applications and research. The pharmaceutical sector represents the largest end‑user segment, followed by academic institutions. Key players including Nitto, Sunresin, and Cytiva dominated the market with approximately 45% combined market share in 2023, with competition intensifying as companies expand their product portfolios and manufacturing capabilities.

---

Explore the full analysis and data:
Nucleic Acid Solid Phase Synthesis Carrier Market – View in Detailed Research Report

---

🔟 1. Nitto Denko Corporation

Headquarters: Tokyo, Japan
Key Offering: Proprietary bead‑based solid‑phase carriers for oligonucleotide synthesis

Leveraging its long‑standing expertise in polymer chemistry, Nitto has positioned itself as a preferred supplier for high‑purity carriers used in antisense and siRNA production. The company’s recent launch of a 200‑base capacity controlled‑pore glass (CPG) line has shortened synthesis cycles by up to 20% for complex oligonucleotides.

Sustainability & Growth Initiatives:

• Investing in recyclable polymer backbones to reduce environmental footprint.
• Deploying AI‑driven process optimization tools across its manufacturing sites.
• Expanding regional production in Southeast Asia to mitigate import tariffs.

---

9️⃣ 2. Sunresin

Headquarters: Shanghai, China
Key Offering: Integrated CPG and polymer carrier solutions for gene‑therapy synthesis

Sunresin’s vertically integrated production chain allows it to control every step of carrier fabrication, ensuring consistent performance for large‑scale oligonucleotide production. The company’s latest eco‑friendly resin line has reduced solvent usage by 30% compared to traditional polystyrene carriers.

Sustainability & Growth Initiatives:

• Partnerships with Chinese biotech incubators to support local mRNA development.
• Implementation of closed‑loop water recycling systems in all manufacturing plants.
• Strategic alliance with a global CRO to accelerate product deployment.

---

8️⃣ 3. Cytiva

Headquarters: Boston, USA
Key Offering: High‑performance carriers with integrated photocleavable linkers for rapid synthesis

As part of the Danaher portfolio, Cytiva offers carriers that combine advanced chemistry with robust scalability. Their latest platform supports oligonucleotide lengths up to 200 bases while maintaining >99.7% coupling efficiency, meeting the strict purity standards required for therapeutic manufacturing.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in resin synthesis.
• Expansion of automated synthesis modules across North American and European sites.
• Investment in digital twins to model and optimize production workflows.

---

7️⃣ 4. Mitsubishi Chemical Group

Headquarters: Tokyo, Japan
Key Offering: Hybrid polymer–glass carriers for high‑throughput oligonucleotide synthesis

Mitsubishi Chemical’s hybrid carriers combine the mechanical stability of glass with the functional versatility of polymer, enabling efficient synthesis of long, modified strands. The company has recently increased its production capacity by 25% to meet rising demand for CRISPR‑based therapeutics.

Sustainability & Growth Initiatives:

• Development of low‑toxicity resin formulations.
• Collaboration with universities to support synthetic biology research.
• Implementation of real‑time quality monitoring sensors.

---

6️⃣ 5. Purolite Corporation

Headquarters: Milwaukee, USA
Key Offering: Ion‑exchange based carriers for specialty oligonucleotide synthesis

Purolite’s ion‑exchange carriers provide an alternative chemistry that enhances the synthesis of modified nucleotides, such as phosphorothioate linkages. The company’s recent product launch has been adopted by several mRNA vaccine developers seeking improved purity.

Sustainability & Growth Initiatives:

• Investing in renewable energy for manufacturing facilities.
• Partnership with a leading AI startup to predict synthesis outcomes.
• Expansion of a dedicated mRNA carrier line.

---

5️⃣ 6. Bio‑Works Technologies AB

Headquarters: Stockholm, Sweden
Key Offering: Custom‑modified carriers for antisense oligonucleotides

Bio‑Works focuses on niche applications, providing carriers with tailored chemistries for antisense therapies. Their recent collaboration with a European pharma giant has resulted in a carrier that reduces synthesis errors by 15% for 100‑base oligonucleotides.

Sustainability & Growth Initiatives:

• Use of biodegradable polymer backbones.
• Implementation of closed‑loop solvent recovery.
• Strategic partnership with a startup developing AI‑assisted synthesis planning.

---

4️⃣ 7. Matrix Dynamics Group

Headquarters: Toronto, Canada
Key Offering: High‑capacity glass carriers for large‑scale oligonucleotide production

Matrix Dynamics has built a reputation for delivering carriers that support high‑throughput synthesis platforms. Their latest glass carrier design achieves coupling efficiencies above 99.8% and supports synthesis lengths up to 200 bases.

Sustainability & Growth Initiatives:

• Development of low‑VOC resin formulations.
• Investment in renewable energy for its Canadian plants.
• Collaboration with a national research institute on CRISPR‑related projects.

---

3️⃣ 8. JNC Corporation

Headquarters: Tokyo, Japan
Key Offering: Hybrid carriers with rapid cleavage linkers for mRNA synthesis

JNC’s carriers feature photocleavable linkers that enable rapid release of synthesized strands, a critical advantage for time‑sensitive mRNA vaccine production. The company has recently secured a contract with a global vaccine manufacturer to supply carriers for a new mRNA platform.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient production lines.
• Partnership with a biotech accelerator to support startup development.
• Deployment of digital monitoring systems for real‑time quality control.

---

2️⃣ 9. Ajax Finechem Pty Ltd

Headquarters: Sydney, Australia
Key Offering: Eco‑friendly polymer carriers for academic research

Ajax Finechem offers carriers that meet the stringent purity requirements of academic labs while maintaining a lower environmental impact. Their recent launch of a fully recyclable polymer line has been adopted by several Australian universities.

Sustainability & Growth Initiatives:

• Use of bio‑based monomers in resin synthesis.
• Collaboration with local universities to develop green chemistry curricula.
• Implementation of a carbon‑offset program for manufacturing emissions.

---

1️⃣ 10. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Advanced carriers for high‑throughput oligonucleotide synthesis

Merck’s carrier platform integrates controlled‑pore glass technology with automated synthesis modules, enabling production of up to 200 bases with high purity. The company’s recent investment in a dedicated mRNA carrier line supports its expanding portfolio of RNA‑based therapeutics.

Sustainability & Growth Initiatives:

• Commitment to zero‑waste manufacturing by 2030.
• Partnership with a German research institute to develop AI‑driven synthesis optimization.
• Expansion of regional production facilities in Europe and Asia to reduce logistics emissions.

---

Download FREE Sample Report:
Nucleic Acid Solid Phase Synthesis Carrier Market – View in Detailed Research Report

---

Get Full Report:
Nucleic Acid Solid Phase Synthesis Carrier Market – View in Detailed Research Report

---

🌍 Outlook: Market Trajectory and Key Growth Levers

The nucleic acid solid‑phase synthesis carrier market is poised to sustain a moderate expansion driven by the continued uptake of oligonucleotide therapeutics and the emergence of mRNA vaccine platforms. North America and Europe remain the largest consumers, but Asia‑Pacific is exhibiting a higher compound growth rate, supported by robust investment in biopharmaceutical manufacturing and a growing ecosystem of contract research organizations.

📈 Future Trends Shaping the Landscape

• Integration of artificial intelligence in synthesis design, enabling real‑time optimization of carrier performance.
• Development of smart carriers with embedded sensors for on‑line purity monitoring.
• Expansion of CRISPR‑based gene editing and mRNA therapies, creating demand for carriers capable of handling highly modified strands.
• Growth of personalized medicine initiatives, driving the need for rapid, high‑throughput synthesis platforms.